Prior authorization criteria for:
Singular®
(montelukast)
Accolate®
(zafirlukast)
COVERED USES:
All FDA-approved indications not otherwise excluded from Part D.
AGE RESTRICTIONS:
NA
PRESCRIBER RESTRICTIONS:
NA
REQUIRED MEDICAL INFORMATION:
For initiation of treatment, a prior authorization form and relevant chart notes documenting medical rationale are required and for continuation of therapy, ongoing documentation of successful response to the medication may be necessary.
CRITERIA:
- There is a diagnosis of asthma OR
- Allergic rhinitis and documentation of an adequate trial of a second-generation antihistamines (example: fexofenadine) and fluticaseon propionate nasal spray.
EXCLUSION CRITERIA:
NA
COVERAGE DURATION:
Initial authorization and reauthorization will be approved for up to one year.